We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
-28.61%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$264M
AUM Growth
-$155M
Cap. Flow
-$10.4M
Cap. Flow %
-3.92%
Top 10 Hldgs %
63.89%
Holding
32
New
1
Increased
–
Reduced
2
Closed
1

Top Buys

1
SRZN icon
Surrozen
SRZN
+$3.6M

Top Sells

1
ELVN icon
Enliven Therapeutics
ELVN
+$6.61M
2
AKRO
Akero Therapeutics
AKRO
+$4.59M
3
TECX
Tectonic Therapeutic
TECX
+$2.77M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRDA icon
1
Entrada Therapeutics
TRDA
$266M
$39.9M 15.07%
4,408,379
– –
ELVN icon
2
Enliven Therapeutics
ELVN
$3.75B
$26M 9.84%
1,322,477
-307,288
-19% -$6.61M
DNTH icon
3
Dianthus Therapeutics
DNTH
$5.59B
$18.6M 7.05%
1,027,711
– –
SKYE icon
4
Skye Bioscience
SKYE
$22.8M
$15.8M 5.96%
9,913,168
– –
PHVS icon
5
Pharvaris
PHVS
$2.43B
$12.5M 4.74%
797,600
– –
CNTA
6
DELISTED
Centessa Pharmaceuticals
CNTA
$11.9M 4.52%
830,945
– –
CAMP icon
7
CAMP4 Therapeutics
CAMP
$185M
$11.7M 4.43%
2,927,915
– –
BHVN icon
8
Biohaven
BHVN
$2.29B
$11.5M 4.35%
478,972
– –
MLTX icon
9
MoonLake Immunotherapeutics
MLTX
$1.66B
$11M 4.17%
282,313
– –
VRDN icon
10
Viridian Therapeutics
VRDN
$1.99B
$9.93M 3.76%
736,595
– –
TECX
11
Tectonic Therapeutic
TECX
$610M
$9.06M 3.43%
511,660
-85,000
-14% -$2.77M
CLDX icon
12
Celldex Therapeutics
CLDX
$2.74B
$9.03M 3.41%
497,270
– –
TYRA icon
13
Tyra Biosciences
TYRA
$1.95B
$8.74M 3.3%
939,298
– –
ERAS icon
14
Erasca
ERAS
$6.65B
$7.41M 2.8%
5,405,404
– –
ARTV
15
Artiva Biotherapeutics
ARTV
$471M
$7.06M 2.67%
2,353,304
– –
ANAB icon
16
AnaptysBio
ANAB
$1.69B
$6.65M 2.52%
357,733
– –
PRAX icon
17
Praxis Precision Medicines
PRAX
$8.81B
$6.44M 2.43%
170,000
– –
GHRS icon
18
GH Research
GHRS
$1.99B
$6.32M 2.39%
572,665
– –
EYPT icon
19
EyePoint Inc
EYPT
$1.14B
$5.69M 2.15%
1,050,000
– –
VKTX icon
20
Viking Therapeutics
VKTX
$4.26B
$4.58M 1.73%
189,593
– –
VOR icon
21
Vor Biopharma
VOR
$972M
$4.56M 1.73%
318,086
– –
SRZN icon
22
Surrozen
SRZN
$244M
$3.61M 1.37%
+310,000
New +$3.6M
TARA icon
23
Protara Therapeutics
TARA
$230M
$3.41M 1.29%
800,000
– –
SCPH
24
DELISTED
scPharmaceuticals
SCPH
$3.16M 1.19%
1,200,647
– –
RLYB icon
25
Rallybio
RLYB
$85.1M
$2.38M 0.9%
453,841
– –
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
BWM
BNC Wealth Management Beaverton, Oregon $360M AUM 49.82% 1-Year Est. Return
LC
Legacy CG Plano, Texas $360M AUM 17.55% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
PWM
Proathlete Wealth Management Boca Raton, Florida $361M AUM 17.13% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return

5AM Venture Management's Q1 2025 Portfolio in Review

As of Q1 2025, 5AM Venture Management held 32 positions worth $264M, down 37% from $419M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

5AM Venture Management withdrew a net $10.4M in Q1 2025, closing 1 position and reducing 2 holdings. Its most notable exit was Akero Therapeutics, an estimated $4.59M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, 5AM Venture Management opened a new position in Surrozen worth $3.61M.

  • 5AM Venture Management's largest Q1 2025 buy was Surrozen: 310,000 shares worth $3.61M.
  • 5AM Venture Management's biggest Q1 2025 reduction was Enliven Therapeutics, cutting an estimated $6.61M.
  • 5AM Venture Management fully exited Akero Therapeutics in Q1 2025, selling an estimated $4.59M.
  • 5AM Venture Management's ten largest holdings make up 64% of its $264M portfolio in Q1 2025.
  • 5AM Venture Management opened 1 new position and closed 1 in Q1 2025.
  • 5AM Venture Management's portfolio value fell 37% quarter-over-quarter to $264M.

Based on 5AM Venture Management's 13F filing for Q1 2025, filed 15 May 2025.